Rapport Therapeutics, Inc.: 10-Q filed 2026-05-07
What Rapport Therapeutics, Inc. reported in its quarterly report filed 2026-05-07 (fiscal Q1 2026): 41 published measures, 85 facts as tagged in accession 0001193125-26-210355.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2026-05-07
- Fiscal period
- fiscal Q1 2026
- Accession
- 0001193125-26-210355 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Rapport Therapeutics, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | 497,597,000 | USD | |
| At 2025-12-31 | 512,431,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | 26,085,000 | USD | |
| At 2025-12-31 | 27,778,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | 471,512,000 | USD | |
| At 2025-12-31 | 484,653,000 | USD | |
| At 2025-03-31 | 285,836,000 | USD | |
| At 2024-12-31 | 305,427,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | 78,056,000 | USD | |
| At 2025-12-31 | 52,645,000 | USD | |
| At 2025-03-31 | 57,604,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | -19,857,000 | USD | 90 |
| 2025-01-01 to 2025-03-31 | -24,063,000 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | -13,061,000 | USD | 90 |
| 2025-01-01 to 2025-03-31 | -20,237,000 | USD | 90 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | 86,000 | USD | 90 |
| 2025-01-01 to 2025-03-31 | 291,000 | USD | 90 |
Contract revenue excluding tax
Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | 20,000,000 | USD | 90 |
| 2025-01-01 to 2025-03-31 | 0 | USD | 90 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | 531,000 | USD | 90 |
| 2025-01-01 to 2025-03-31 | 5,000 | USD | 90 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | 37,941,000 | USD | 90 |
| 2025-01-01 to 2025-03-31 | 21,031,000 | USD | 90 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | -255,085,000 | USD | |
| At 2025-12-31 | -235,228,000 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | 47,236,618 | shares | 90 |
| 2025-01-01 to 2025-03-31 | 35,266,577 | shares | 90 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | 47,236,618 | shares | 90 |
| 2025-01-01 to 2025-03-31 | 35,266,577 | shares | 90 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | -0.42 | USD/shares | 90 |
| 2025-01-01 to 2025-03-31 | -0.68 | USD/shares | 90 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | -0.42 | USD/shares | 90 |
| 2025-01-01 to 2025-03-31 | -0.68 | USD/shares | 90 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | 2,518,000 | USD | |
| At 2025-12-31 | 2,976,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | 6,963,000 | USD | 90 |
| 2025-01-01 to 2025-03-31 | 4,040,000 | USD | 90 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | -24,215,000 | USD | 90 |
| 2025-01-01 to 2025-03-31 | -27,108,000 | USD | 90 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | 484,695,000 | USD | |
| At 2025-12-31 | 498,561,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | 17,897,000 | USD | |
| At 2025-12-31 | 19,049,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | 6,561,000 | USD | |
| At 2025-12-31 | 4,190,000 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | 58,000 | USD | |
| At 2025-12-31 | 0 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | 44,215,000 | USD | 90 |
| 2025-01-01 to 2025-03-31 | 27,108,000 | USD | 90 |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | 11,499,000 | USD | 90 |
| 2025-01-01 to 2025-03-31 | 7,536,000 | USD | 90 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | 32,716,000 | USD | 90 |
| 2025-01-01 to 2025-03-31 | 19,572,000 | USD | 90 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | 47,807,453 | shares | |
| At 2025-12-31 | 47,772,567 | shares |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | -505,000 | USD | |
| At 2025-12-31 | 546,000 | USD |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | 9,327,000 | USD | |
| At 2025-12-31 | 9,909,000 | USD |
Gross property, plant and equipment
Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | 4,448,000 | USD | |
| At 2025-12-31 | 4,958,000 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | 1,930,000 | USD | |
| At 2025-12-31 | 1,982,000 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | 1,057,000 | USD | |
| At 2025-12-31 | 985,000 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | 8,721,000 | USD | |
| At 2025-12-31 | 12,104,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-03-31 | 7,750,000 | USD | |
| At 2025-12-31 | 7,917,000 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | -19,857,000 | USD | 90 |
| 2025-01-01 to 2025-03-31 | -24,063,000 | USD | 90 |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | -20,908,000 | USD | 90 |
| 2025-01-01 to 2025-03-31 | -23,636,000 | USD | 90 |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | -19,857,000 | USD | 90 |
| 2025-01-01 to 2025-03-31 | -24,063,000 | USD | 90 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | 200,000 | USD | 90 |
| 2025-01-01 to 2025-03-31 | 200,000 | USD | 90 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | 227,000 | USD | 90 |
| 2025-01-01 to 2025-03-31 | 244,000 | USD | 90 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | 4,358,000 | USD | 90 |
| 2025-01-01 to 2025-03-31 | 3,045,000 | USD | 90 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | 58,000 | USD | 90 |
| 2025-01-01 to 2025-03-31 | 0 | USD | 90 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-03-31 | 2,305,000 | USD | 90 |
| 2025-01-01 to 2025-03-31 | 185,000 | USD | 90 |
Inspect the source
- Entity
- Rapport Therapeutics, Inc. / CIK 0002012593
- Captured
- 2026-09-21T17:40:38.590Z
- SEC response SHA-256
c85599e790354d601ba4d1fe529289653292200857d79f1a88fcf306fd63be80
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0002012593.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))